Anesthesia and Critical Care Reviews and Commentary (ACCRAC) Podcast
Episode 291: Psychedelics for Chronic Pain and Depression with Patrick Finan and Rebecca Ehrenkranz
Sep 22, 2024
Join Patrick Finan, an expert in pain psychology and psychedelics research, and Rebecca Ehrenkranz, a postdoctoral researcher at Johns Hopkins, as they explore groundbreaking uses of psychedelics for chronic pain and depression. They discuss the transition from research to clinical trials involving substances like psilocybin and LSD. Hear about the complexities of managing expectations in trials, the role of active placebos, and the emotional breakthroughs psychedelics can provide. Plus, get insights on participant recruitment and some fun book and music recommendations!
54:07
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Psychedelics like psilocybin interact primarily with serotonin receptors, potentially leading to significant and lasting improvements in mood and emotional states.
- Expectancy plays a crucial role in the therapeutic effects of psychedelics, influencing patient perceptions and experiences during clinical trials.
Deep dives
Psychedelics and Their Mechanisms
Classic psychedelics, such as psilocybin, LSD, and mescaline, exert their effects primarily through the serotonin 5-HT2A receptors, influencing mood and cognitive functions. These substances can produce significant perceptual alterations and emotional states, often allowing individuals to experience increased feelings of connectedness and joy. Research suggests that the effects of these psychedelics can have long-lasting positive outcomes on mental well-being, potentially persisting even a year post-experience. However, it is essential to recognize that adverse experiences, such as challenging emotions and ego dissolution, may also occur during psychedelic use.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
